Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

3i Infrastructure expects to hit targets with annual results

(Sharecast News) - Infrastructure investment group 3i Infrastructure said trading towards the end of its financial year has been in line with expectations with its portfolio performing well and delivering strong earnings growth. The company said it remains on track to deliver its dividend target of 11.9p per share for the year ending 31 March, up 6.7% on the year before.

"We expect to report returns for the period in line with our target, driven by continued earnings momentum at our larger assets," said Scott Moseley and Bernardo Sottomayor, managing partners and co-heads of European Infrastructure at 3i Investments, the investment manager of the company

"Following the outperformance achieved in the first half, this is another strong year for 3iN."

Income and non-income cash is said to be slightly ahead of expectations for the year at £104m in the second half, in line with the first half.

The stock was up 0.4% at 7,959.45p by 0913 GMT.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.